Small molecule · developed by LeonaBio
Fosgonimeton (ATH-1017, NDX-1017) is a drug given as a subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04488419 | Phase 2/3 | Alzheimer Disease | Completed | LONA |
| NCT05511558 | Phase 1 | Healthy Volunteers | Completed | LONA |
| NCT03298672 | Phase 1 | Alzheimer Disease | Completed | LONA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseaseDementia of Alzheimer TypeHealthy Volunteers
Updated Oct 18, 2026. Something wrong or missing? Report it on the LONA page.
See LONA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LONA catalysts and pipeline →